CA2372738A1 - Recuperation de cellules photoreceptrices induite par il-1.beta. administree a faible dose et ne provoquant pas de dysplasie retinienne - Google Patents

Recuperation de cellules photoreceptrices induite par il-1.beta. administree a faible dose et ne provoquant pas de dysplasie retinienne Download PDF

Info

Publication number
CA2372738A1
CA2372738A1 CA002372738A CA2372738A CA2372738A1 CA 2372738 A1 CA2372738 A1 CA 2372738A1 CA 002372738 A CA002372738 A CA 002372738A CA 2372738 A CA2372738 A CA 2372738A CA 2372738 A1 CA2372738 A1 CA 2372738A1
Authority
CA
Canada
Prior art keywords
beta
composition
dystrophic
retinal
retina
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002372738A
Other languages
English (en)
Inventor
Michael J. Young
Simon J. Whiteley
Henry Klassen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Schepens Eye Research Institute Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2372738A1 publication Critical patent/CA2372738A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention se rapporte à l'administration de faibles doses d'interleukine IL-1.beta., inférieures ou égales à 50 µg/ml et de préférence inférieures ou égales à 10 g$(m)g/ml, qui peut encore induire une récupération de cellules neuronales telles que les cellules photoréceptrices, et n'entraîner qu'un minimum de séquelles destructrices, du type dysplasie rétinienne et inflammation intraoculaire.
CA002372738A 1999-05-06 2000-05-08 Recuperation de cellules photoreceptrices induite par il-1.beta. administree a faible dose et ne provoquant pas de dysplasie retinienne Abandoned CA2372738A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13285599P 1999-05-06 1999-05-06
US60/132,855 1999-05-06
PCT/US2000/012565 WO2000068267A1 (fr) 1999-05-06 2000-05-08 RECUPERATION DE CELLULES PHOTORECEPTRICES INDUITE PAR IL-1β ADMINISTREE A FAIBLE DOSE ET NE PROVOQUANT PAS DE DYSPLASIE RETINIENNE

Publications (1)

Publication Number Publication Date
CA2372738A1 true CA2372738A1 (fr) 2000-11-16

Family

ID=22455907

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002372738A Abandoned CA2372738A1 (fr) 1999-05-06 2000-05-08 Recuperation de cellules photoreceptrices induite par il-1.beta. administree a faible dose et ne provoquant pas de dysplasie retinienne

Country Status (5)

Country Link
EP (1) EP1179020A4 (fr)
JP (1) JP2003525206A (fr)
AU (1) AU4994000A (fr)
CA (1) CA2372738A1 (fr)
WO (1) WO2000068267A1 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5667968A (en) * 1989-08-30 1997-09-16 Regeneron Pharmaceuticals, Inc. Prevention of retinal injury and degeneration by specific factors
ATE193207T1 (de) * 1992-02-14 2000-06-15 Regeneron Pharma Vorbeugung von verletzungen und degenerationen von photorezeptoren durch neurotrophische faktoren

Also Published As

Publication number Publication date
EP1179020A1 (fr) 2002-02-13
AU4994000A (en) 2000-11-21
JP2003525206A (ja) 2003-08-26
EP1179020A4 (fr) 2004-08-18
WO2000068267A1 (fr) 2000-11-16
WO2000068267A9 (fr) 2001-06-14

Similar Documents

Publication Publication Date Title
DE60021760T2 (de) Verfahren zur verabreichung von wirkstoffen in das zentrale nervensystem oder lymphsystem
US7282482B2 (en) NGF for the prevention of demyelination in the nervous system
BROD et al. Modification of acute experimental autoimmune encephalomyelitis in the Lewis rat by oral administration of type 1 interferons
EP1740200B1 (fr) Il-6 pour traitement ou prevention d'une neuropathie induite par une chimiotherapie
EP0610336B1 (fr) Traitement des troubles neurologiques a l'aide d'un compose inhibant l'interleukin-1
Whiteley et al. Photoreceptor rescue after low-dose intravitreal IL-1β Injection in the RCS Rat
CA2372738A1 (fr) Recuperation de cellules photoreceptrices induite par il-1.beta. administree a faible dose et ne provoquant pas de dysplasie retinienne
US6225300B1 (en) TNF receptor and steroid hormone in a combined therapy
JP6279905B2 (ja) 速い用量調節の漸増投与レジメンを用いた、インターフェロンの筋肉内投与に伴うインフルエンザ様症状を軽減するための方法
JPH09510737A (ja) 化学療法剤を増強するためのｉｌ−４の使用
US8106096B2 (en) Compositions and methods for treatment of optic nerve diseases
DE60019921T2 (de) Verwendung von interleukin-11 zur behandlung von hämoragischem schock
US7012060B1 (en) TNF receptor and steroid hormone in a combined therapy
GB2241891A (en) Tumour necrosis factor compositions for treating inflammatory disease
EP1602378A1 (fr) Méthode d'administration d'une cytokine au système nerveux central et au systéme lymphatique
BA32 TGF-B (pglml)
ZA200502301B (en) Treatment of allergic conditions by use of il21.

Legal Events

Date Code Title Description
FZDE Dead